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Abstract
Context: Genetic testing for monogenic diabetes is important for patient care. Given the extensive genetic and clinical
heterogeneity of diabetes, exome sequencing might provide additional diagnostic potential when standard Sanger
sequencing-based diagnostics is inconclusive.
Objective: The aim of the study was to examine the performance of exome sequencing for a molecular diagnosis of MODY
in patients who have undergone conventional diagnostic sequencing of candidate genes with negative results.
Research Design and Methods: We performed exome enrichment followed by high-throughput sequencing in nine
patients with suspected MODY. They were Sanger sequencing-negative for mutations in the HNF1A, HNF4A, GCK, HNF1B and
INS genes. We excluded common, non-coding and synonymous gene variants, and performed in-depth analysis on filtered
sequence variants in a pre-defined set of 111 genes implicated in glucose metabolism.
Results: On average, we obtained 45 X median coverage of the entire targeted exome and found 199 rare coding variants
per individual. We identified 0–4 rare non-synonymous and nonsense variants per individual in our a priori list of 111
candidate genes. Three of the variants were considered pathogenic (in ABCC8, HNF4A and PPARG, respectively), thus exome
sequencing led to a genetic diagnosis in at least three of the nine patients. Approximately 91% of known heterozygous
SNPs in the target exomes were detected, but we also found low coverage in some key diabetes genes using our current
exome sequencing approach. Novel variants in the genes ARAP1, GLIS3, MADD, NOTCH2 and WFS1 need further
investigation to reveal their possible role in diabetes.
Conclusion: Our results demonstrate that exome sequencing can improve molecular diagnostics of MODY when used as
a complement to Sanger sequencing. However, improvements will be needed, especially concerning coverage, before the
full potential of exome sequencing can be realized.
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Introduction
MODY (maturity-onset diabetes of the young) is a heteroge-
neous group of diabetes caused by single gene defects in at least ten
genes affecting pancreas development and beta-cell function
[1,2,3]. The most common MODY forms are caused by mutations
in the glucokinase gene (GCK) [4] and the hepatocyte transcription
factor genes HNF1A and HNF4A [5,6]. GCK-MODY (MODY2) is
a mild disease manifesting as slightly elevated fasting glucose, well
controlled without medical treatment, and no risk for late diabetes-
associated complications [7,8]. In contrast, HNF1A- and HNF4A-
MODY (MODY3 and MODY1, respectively) typically lead to
progressive beta-cell dysfunction and high risk for late complica-
tions and patients often benefit from sulfonylurea treatment
[9,10,11]. HNF1B-mutations result in a syndromic diabetes form
(MODY5), which includes renal failure, genital and pancreatic
malformations, and liver dysfunction [12,13] According to the
OMIM database, mutations in seven other genes (BLK, CEL, INS,
KLF11, NEUROD1, PAX4, PDX1) can cause inherited diabetes
with a MODY phenotype. There are also other forms of
monogenic diabetes such as neonatal diabetes that presents before
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than diabetes dominates the clinical pictures (reviewed in [1]).
Genetic testing in monogenic diabetes is important for diagnosis
and treatment [1,2,3]. When MODY is suspected, the current
approach involves PCR amplification and Sanger sequencing of
candidate genes, frequently with an iterative approach based on
clinical features. For example, most laboratories will first screen
HNF1A, followed by HNF4A and GCK in subjects exhibiting the
classical features of MODY; and first GCK, then HNF1A and
HNF4A, if the diabetic phenotype is mild and fasting glucose 5.5–
8.5 mmol/l [1,2]. If the patient presents with renal dysfunction,
urogenital or pancreatic malformations, HNF1B is usually the first
gene that is tested [1,2].
Although systematic studies are lacking, our experience is that
molecular genetic testing reveals a mutation in one of the
common MODY genes in about 50% of probands referred to
our laboratory. The remaining cases would also benefit from
a genetic diagnosis, but the cost of sequencing other candidate
genes often precludes further testing. A standard, complete
investigation of HNF1A, HNF4A and GCK includes sequencing
of 31 exons, where each sequencing reaction must be evaluated
separately. Hence, the current approach is expensive and time-
consuming, and establishes a molecular diagnosis only among
a limited number of genes. Whole-exome capture and high-
throughput sequencing has a great potential to detect causal
gene variants in dominant and recessive disorders as well as in
diseases due to de novo mutations [14,15,16,17,18]. Here, we
describe our experience using exome sequencing in MODY
patients referred to us for genetic testing.
Materials and Methods
Ethics Statement
The study was approved by the Regional Ethical Committee for
Medical Research West and performed according to the Helsinki
Declaration. We obtained verbal and written informed consent
from the study participants.
Study Population
We carried out whole-exome sequencing on nine probands with
MODY of unknown cause recruited from the Norwegian MODY
Registry (Figure 1 and Table 1). There was diabetes running in the
families for at least three generations, autosomal dominant
inheritance and age at diagnosis 11–28 years for at least one
family member. All probands were negative for mutations in
HNF1A, HNF4A, GCK, HNF1B and INS by Sanger sequencing.
Targeted Capture and Massive Parallel Sequencing
Targeted capture and massive parallel sequencing were
performed at HudsonAlpha Institute for Biotechnology (Hunts-
ville, AL) (File S1). In brief, SureSelect Human All Exon Kit
(Agilent Technologies, Santa Clara, CA) was used for exome
enrichment, and sequencing was performed on Genome Analyzer
GAIIx (Illumina Inc., San Diego, CA). Samples were sequenced
on one lane for paired-end 72-bp reads, and the samples with
lowest yield were complemented with one additional lane of single-
read 76-bp reads (P01, P03, P04, P05 P07).
Read Mapping and Variant Analysis
We mapped paired-end-reads and single-reads to the reference
human genomes (UCSC NCBI37/hg19) using Burrows-Wheeler
Alignment tool (BWA) [19] (see also supporting Materials and
Methods File S1). PCR duplicates were removed with PICARD
(http://picard.sourceforge.net) followed by base quality recalibra-
tion using GATK [20]. SNPs and indels were called by SAMtools
[21] mpileup, correcting for overestimated mapping quality from
BWA. SNPs were filtered by the following criteria: (1) SNPs should
not be in a cluster with window-size of 10 bp, (2) sequencing depth
should be at least 8 X; and (3) quality score should be $30. We
used Annovar [22] (Nov 22, 2011) and in-house scripts to annotate
and filter variants after variant calling. The performance of our
exome sequencing variant calling pipeline was tested against
heterozygous genotypes present in the enrichment target regions
derived from the Affymetrix 6.0 whole-genome genotyping array
in seven of the individuals (File S1).
In silico Analyses of Candidate Variants
We evaluated possible functional significance of the variants
using PolyPhen v2.0.23 [23], Align-GVGD (http://agvgd.iarc.fr)
and SIFT (http://sift.jcvi.org/), see File S1.
Selection of genes of Interest
We selected genes previously implicated in monogenic diabetes
and related syndromes [1,24], genes with important roles in the
beta cell [25,26] and genes implicated from whole-genome-
significant SNP associations with type 2 diabetes (T2D) or fasting
glucose [24,27,28,29,30,31]. For the T2D and fasting glucose-
associated regions, we selected named gene/genes highlighted in
the respective publications. Notably, experimental evidence di-
rectly supporting that these genes are responsible for the
associations, is mostly lacking. The 111 genes, of which 109 were
included in the capture assay, totaled 272 kb of exonic sequence
(Table S1).
Rare Variant Validation
All variants in the candidate mutation set were validated by
PCR amplification of the variant-containing exon from the
original patient sample, followed by Sanger sequencing. Frequen-
cy estimates were generated by genotyping 340 Norwegian healthy
controls using the MassARRAY iPLEX system or by Sanger
sequencing.
Results
By sequencing the exomes of the nine MODY probands
(Table 1, Figure 1), we obtained 3.5–5.8 Gb mapable sequence
per sample with 36–57 X median coverage of the targeted exome
and 88–93% of the exome targeted at least eight times (Table 2).
The candidate diabetes genes showed similar coverage (Tables S1
and S2). The exceptions were DGKB and THADA, which were not
present on the exome enrichment array highlighting one problem
with our approach: current target capture reagents may not
include all exons of interest. The MODY genes HNF4A and
HNF1B showed relatively good coverage ($87%, at 8X) through-
out the entire coding regions, while GCK (83%), HNF1A (72%) and
INS (58%) were less uniformly covered (Tables S1 and S2).
We identified an average of 14,463 substitutions and indels per
sample (in the targeted exome) after quality control (Table 3). The
quality of the data was investigated by comparisons from 7,800
genotyped SNPs, present in the Agilent capture region, and
obtained from the Affymetrix 6.0 genotyping array for seven of the
nine individuals. Between 89 and 92% of the heterozygous
genotyping-array-SNPs present in the capture regions were
detected (File S1 and Table S3).
Next, we developed a data reduction pipeline consisting of
several steps (Table 3). We first excluded all variants not present
in the actual coding sequence or in splice sites; and synonymous
variants other than those occurring at canonical splice sites. We
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variants from 50 Norwegian whole exomes and finally excluded
variants with minor allele frequencies .0.5% of the 1000
Genomes Project. This reduced the number to 183–213 rare,
coding single-nucleotide substitutions and coding indels per
individual (Table 3). Combining all nine individuals, this
Figure 1. Partial pedigrees of the nine MODY families investigated. Squares represent male family members, circles female, and diamonds
sex unknown. Numbers inside diamonds show the number of siblings. Black and grey symbols represent persons with diabetes and impaired glucose
tolerance, respectively. An arrow denotes the proband in each family and stars indicate those subjects for whom DNA was available. Data under the
symbols represent from top to bottom: age at diabetes diagnosis, mutation carrier status (N=Normal allele, M=Mutation), BMI and treatment (INS=
Insulin, OHA=Oral Hypoglycemic Agents).
doi:10.1371/journal.pone.0038050.g001
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genes. Only 50 variants were present in more than one of the
nine individuals. On the gene level, 266 genes were listed with
rare (most often different) variants in more than one individual,
and 24 genes with rare variants in three or more individuals.
Hence, despite our rigid procedure for variant filtration, a large
number of potential candidate genes emerged from the nine
patient data sets.
We then focused on the candidate gene list (Table S1). We
identified 14 rare coding variants in 12 genes of the 111
candidate genes. Thirteen of the variants were verified by
Sanger sequencing (Tables 3 and 4). Frequency estimates in 340
healthy controls, computational methods to estimate deleteri-
ousness and literature searches were performed for the
remaining 13 variants (Table 4). When available, additional
family members were sequenced for variants not present in
either the 1000 G database, dbSNP or in our 340 Norwegian
controls (Figure 1).
Table 1. Clinical characteristics of the nine MODY probands investigated.
Proband P01
a P02 P03 P04 P05 P06 P07 P08 P09
S e x FM FFF F M M M
Age of diabetes diagnosis (y) 38
b 24 25 24 19 11 25 28 14
Number of generations with DM 33343 4 333
Current status
Age (y) 68 52 38 31 55 16 35 35 29
BMI 30.1 21.4 29.9 27.2 28.3 31.5 24.3 24.6 25.3
Insulin dose (U/kg/day) 2.2 0.4 0 0.8 0.7 2.0 0.8 NA 0.5
OHA Yes No Yes Yes No Yes No No No
Glycosylated hemoglobin (%) 7.5 6.1 9.0 6.7 7.1 8.4 7.2 9.3 6.4
Other clinical features
Hypertension Yes No No No Yes Yes Yes No No
Hypercholesterolemia Yes No No No Yes Yes No No No
Retinopathy Yes No No No Yes No Yes No No
Nephropathy Yes No No No No No No No No
Arteriosclerosis Yes No No No No No No No No
Polyneuropathy Yes No No No Yes No No No No
None of the individuals had hearing loss or acantosis nigricans. Data regarding hepatic steatosis, renal cysts, polycystic ovarian disease and triglyceride status were not
available in all individuals.
aP01 also had partial lipodystrophy with reduced subcutaneous fat in extremities and excess of abdominal subcutaneous fat. There was no evidence of
hypertriglyceridemia, hepatic steatosis, acanthosis nigricans or polycystic ovarian disease.
bAn affected family member was diagnosed at age 28 years.
Abbreviations: BMI, body mass index; DM, diabetes mellitus; NA, not available; OHA, Oral Hypoglycemic agents; U, international unit (used for insulin doses); y, year; kg,
kilo gram body weight.
doi:10.1371/journal.pone.0038050.t001
Table 2. Overall exome coverage and target gene set coverage statistics.
Percentage at $ Percentage at $
Sample ID
Unique Gbs
aligned Median (X) 8X 20X Median (X) 8X 20X
P01 3.5 36 89 71 33 85 66
P02 3.5 36 88 71 34 86 68
P03 4.8 50 92 79 46 89 75
P04 5.5 57 92 81 52 90 77
P05 5.4 55 92 8 49 89 76
P06 3.6 39 89 73 35 85 68
P07 5.8 59 93 82 55 90 78
P08 3.7 39 89 73 37 86 69
P09 3.5 37 89 71 35 86 68
Average 4.4 45 90 76 42 87 72
doi:10.1371/journal.pone.0038050.t002
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Known to Cause Autosomal Dominant Disease
In subject P01, we identified the heterozygous nonsense
mutation c.1071G.A/p.R357X introducing a premature stop
codon in PPARG exon 7. This mutation has previously been shown
to cause severe insulin-resistant diabetes and partial lipodystrophy
[32,33,34]. The proband’s age at diagnosis was 38 years; she was
included in our study because a family member was diagnosed at
age 28 years. The proband’s BMI was 27.6 kg/m
2 in 2002,
30.1 kg/m
2 in 2010, and her insulin requirement has in the same
period increased from 1.4 to 2.2 U/kg/day. There was a high
prevalence of micro- and macro-vascular complications in most of
the affected family members, although none were available for
genetic testing (Table 1, Figure 1). Thus, at recruitment the
proband had a MODY phenotype, but was insulin-resistant on
follow-up. The same mutation has been reported in patients with
a similar clinical picture [32,33,34]. We consider this mutation
pathogenic.
In subject P03, we detected the novel and heterozygous non-
synonymous ABCC8 mutation c.4096G.A/p.A1366T. Amino
acid 1366 is highly conserved and located in the ATP-binding
domain. Other nearby amino acid substitutions are associated with
either congenital hyperinsulinism or neonatal/adult-onset diabetes
[35,36]. The proband was diagnosed with diabetes at 25 years of
age and is currently treated with sulfonylurea and metformin. All
four diabetic family members (none available for genetic testing)
were treated with OHA. The proband’s age at diagnosis was late
for ABCC8 diabetes although other such cases have been described
[35,37,38,39]. The large size of ABCC8 makes it less amenable to
Sanger-based mutation screening, which may underestimate the
role of this gene in MODY. Since the proband was sulfonylurea-
sensitive, we categorized p.A1366T as being probably pathogenic.
Further sequencing studies of unselected MODY patients will
Table 3. Overview of all substitutions and indels detected in the nine probands before and after variant reduction.
Patients
Variants and filter P01 P02 P03 P04 P05 P06 P07 P08 P09 Average
All exonic 14102 14219 14773 14974 14668 14253 14720 14190 14269 14463
Exonic coding 6460 6582 6776 6855 6634 6526 6744 6557 6565 6633
Not in in-house database (50
samples)
250 215 263 255 252 255 264 267 260 253
Not in 1000 G .0.5% 193 183 197 202 197 197 202 213 206 199
Candidate variants in 111 target
genes
123120104 2
doi:10.1371/journal.pone.0038050.t003
Table 4. Rare coding variants identified in the 111 target candidate genes using whole exome sequencing in nine patients with
suspected MODY.
Gene Chr:Position Variant
dbSNP132/1000 G
b
frequency
Frequency in
340 Norwegian
controls
SIFT/
PolyPhen-2/
AlignGVGD
a Patient Conclusion
ABCC8 11:17418486 c.4096G.A/p.A1366T 2/0 0 2/+/C55 P03 Pathogenic
ALMS1 2:73677199 c.3542C.T/p.T1181I 2/0 0.1% n.a/+/n.a. P09
ARAP1 11:72421497 c.1349G.A/p.R450H 2/0 0 +/2/C0 P04
CRY2 11:45893711 c.1528G.C/p.G510R 2/0 0.1% 2/2/C15 P02
GLIS3 9:4286332 c.94C.G/p.R32G 2/0 0 +/+/C0 P03
HADH 4:108940732 c.456G.T/p.Q152H rs1051519/0.2% - 2/2/C0 P09
HNF4A 20:43034848 c.266G.A/p.R89Q 2/0 0 +/++/C35 P07 Pathogenic
MADD 11:47317569 c.3479G.C/p.S1160T 2/0 0 2/++/C55 P02
NOTCH2 1:120468211 c.4228C.T/p.R1410C 2/0 0 +/+/C25 P05
1:120478125 c.3625T.G/p.F1209V 2/0 0.4% +/+/C45 P03
1:120548095 c.272G.T/p.R91L FALSE FALSE FALSE P05 False positive
PPARG 3:1258536 c.1071G.A/p.R357X 2/0 0 Nonsense P01 Pathogenic
SREBF1 17:17718592 c.2435G.A/p.R812Q 2/0 1.0% 2/2/C0 P09
WFS1 4:6354530 c.2107C.T/p.R703C 2/0 0 +/++/C65 P09
aSIFT: 2 tolerated, + not tolerated/PolyPhen-2: 2 benign, + possibly damaging, ++ probably damaging/Align-GVGD: the Grantham variation (GV), and the Grantham
deviation (GD) are combined to provide graded classifiers from most likely to interfere with function (class C65) to least likely (class C0).
bAllele frequencies from the interim analysis of phase I of the 1000 Genomes Project, 2010.08.04 sequence index, which included 629 samples (SNPs released in
November 2010, indels released in February 2011).
Abbreviation: Chr, chromosome number; 1000 G, the 1000 Genomes Project; n.a, not analysed due to insufficient number of alignments to make prediction.
doi:10.1371/journal.pone.0038050.t004
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previously anticipated.
In subject P07, we identified a novel non-synonymous mutation
c.266G.A/p.R89Q in HNF4A. This was surprising since HNF4A
already had been screened. Sanger re-sequencing confirmed the
mutation. When re-examining the first electropherogram, the
mutation was detectable. Hence, it had been overlooked. Another
substitution of the same codon, c.265C.T/p.R89W, has been
identified in MODY [40]. The amino acid residue at position 89
of HNF4A is highly conserved from Drosophila to humans and part
of the DNA binding domain. Both parents are of normal weight
but developed diabetes in their early forties (Figure 1). Sanger
sequencing revealed that the mutation was inherited from the
maternal side of the family that appears to have a stronger history
of diabetes. After receiving the molecular diagnosis the proband
made a successful transfer from insulin to sulfonylurea. We
consider the mutation p.R89Q pathogenic.
Other Rare Variants in the Candidate Gene Set
In the 111 candidate genes, we also identified novel (not present
in 50 in-house exomes, 340 healthy controls or 1000 Genomes)
variants in potentially interesting genes implicated in susceptibility
to diabetes, albeit thus far not in an autosomal dominant mode of
inheritance: ARAP1, GLIS3, MADD, NOTCH2 and WFS1 (Table 4).
Each genetic variant is discussed in some detail below.
In subject P02, we detected the novel and heterozygous non-
synonymous MADD variant c.3479G.C/p.S1160T. The MADD
(MAP-kinase activating death domain) protein is known to have
a role in apoptosis [41] and SNPs in the MADD region are
associated with elevated pro-insulin and fasting glucose levels [42].
The subject was diagnosed with diabetes at 24 years of age. He has
for ten years been treated with sulfonylurea and is currently on
insulin (0.5 U/kg/day). C-peptide and proinsulin were detectable,
however, not elevated. The affected and lean brother also carried
the variant. He was diagnosed with diabetes 39 years old and is
treated with oral hypoglycaemic agents (OHA). No other family
members were available for genetic analysis.
Individual P03 (who had a probably pathogenic ABCC8
mutation) also had a potentially interesting variant in GLIS3
which is a transcription factor expressed in beta-cells and
important for insulin gene expression [43]. Mutations in GLIS3
can cause a recessive form of neonatal diabetes and congenital
hypothyroidism (OMIM#610199) [44,45]. There are, however,
no reports on dominant GLIS3 mutations, and the variant is
located in a protein region with no known function. With only the
proband available for genetic testing, it was not possible to study
the segregation of the variant in the family. We consider that the
ABCC8 mutation is more likely to be the pathogenic variant in this
patient.
In subject P04, we detected the ARAP1 (previously CENTD2)
variant c.1349G.A/p.R450H. It is predicted to be benign by
PolyPhen and AlignGVGD (Table 4) but damaging by SIFT, and
it co-segregates with diabetes in the core family (Figure 1).
Common variants at this locus have been associated with type 2
diabetes, fasting glucose and pro-insulin level [28,46,47], and it is
suggested that this effect is mediated through reduced insulin
secretion capacity [46,47]. However, as with most GWAS-
associated regions, the causative variant has not yet been
pinpointed, and the nearby STARD10 gene was recently suggested
as a better biological candidate gene in the region [47]. Although
not on our original candidate gene list, in retrospect, no rare
variants were detected in STARD10.
The NOTCH2 variant c.4228C.T/p.R1410C, found in P05,
did not co-segregate with diabetes (Figure 1). This gene was
implicated as a type 2 diabetes locus in a recent GWAS meta-
analysis [28]. It is also known that heterozygous mutations in
NOTCH2 can cause Alagille syndrome (OMIM#610205) and
Hajdu-Cheney syndrome (OMIM #102500). The patient showed
no symptoms suggesting any of these diseases.
In subject P09, we detected the novel WFS1 variant c.2107C/
T/p.R703C. The affected amino acid residue is strongly
conserved and the variant is suggested to be probably damaging
by all three prediction programs (Table 4). Recessive mutations in
WFS1 can lead to Wolfram syndrome (OMIM #222300), which
includes diabetes, hearing impairment and psychiatric disease,
while heterozygous carriers appear to show no major symptoms
associated with diabetes. Wfs1 null mice and genetic association
studies suggest a role in insulin secretion [48,49]. The proband
developed diabetes 14 years old with no type 1 auto-antibodies
and currently requires 0.5 U/kg/day insulin. There was no
familial hearing impairment. The affected brother and father
carried the variant, but not the affected uncle (Figure 1). Age-of-
diagnosis and insulin requirements are distinctly different between
the affected brothers and their father and uncle.
Discussion
Exome sequencing has shown a great potential for identification
of disease mutations in monogenic disorders [14,15,16,17,18].
However, it is not clear how representative the early proof-of-
principle studies are and whether this technology is ready to
replace or complement traditional Sanger sequencing for clinical
genetic testing.
Here, we show that exome sequencing can provide a significant
diagnostic advantage in a substantial fraction of patients where
Sanger sequencing often is inefficient, such as cases with atypical
clinical presentation (family P03) or when clinical information is
limited (family P01). For this group of patients, exome sequencing
is an attractive option compared to the current ‘‘phenotypically’’
driven genetic testing as it allows testing beyond the short list of
genes typically tested by Sanger sequencing.
To illustrate how this technology could be utilized for routine
diagnostic use, we restricted our analysis to a list of 111 candidate
genes. Our list included known disease genes for monogenic
diabetes, insulin resistance and diseases related to glucose
homeostasis. We also explored rare variants in candidates such
as genes encoding transcription factors important for pancreatic
development and islet specification/differentiation [25,26], and
genes identified in GWAS of diabetes and fasting glucose levels.
Our study identified some rare variants in the latter gene
categories (Table 4 and results section). Although these variants
are located in attractive candidates, to claim causality would
obviously require much more extensive proof than for genes
already known to cause autosomal-dominant diabetes. Such
evidence would include co-segregation between variant and
disease in large families, the presence in other subjects with
a similar phenotype together with functional and clinical studies.
Especially the limed number of available family members for
segregation analysis, does not allow us to reach this level of support
for the variants in our ‘‘candidate gene’’ category. Hence, we
could not determine whether these variants are causing MODY or
at least may act as polygenic risk factors that warrant further
investigations (Table 4).
A possible advantage with exome sequencing is that it also
allows for an extensive search for completely novel diabetes genes
in individuals with no genetic defect in the known diabetes genes.
However, for diabetes, where the genes for several monogenic
forms already have been detected [1], the search for remaining,
Exome Sequencing in MODY
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clinical heterogeneity. Our registry-based clinical sample with
limited access to extended pedigrees was not powered to identify
novel disease genes among the approximately 200 rare coding
variants in each individual. Thus, international efforts to sequence
the entire exomes of larger numbers of carefully selected subjects
and to identify large multi-generational diabetes families may be
a way forward.
For diagnostic utility, our study reveals that exome sequencing
can increase the possibility for a genetic diagnosis in MODY. The
coverage for certain key genes must, however, be improved before
exome sequencing can replace Sanger sequencing in routine
molecular diagnostics. Recent and ongoing improvements in
capture hybridization and high-throughput sequencing technolo-
gies are promising, but the coverage problem may not be solved
completely by new enrichment kits, higher read depths and longer
reads. In the meantime, it might be attractive to use tailored
hybridization capture for the disease of interest followed by very
high-coverage sequencing of the disease-specific gene panels [50].
The increased coverage for the target genes must be weighted
against the cost of developing, optimizing and keeping up-to-date
disease-specific gene panels and the limited ability to detect
unexpected phenotype-genotype correlations.
In conclusion, we consider phenotypically driven Sanger
sequencing still as the first choice for genetic testing in patients
with classical features of MODY. Exome sequencing is currently
an important complement when Sanger sequencing is negative, or
in patients with atypical clinical presentation. In the near future,
we believe that tailored hybridization capture for selected genes of
interest and very high-coverage sequencing of specific gene panels
will replace Sanger sequencing. Ongoing refinements in the design
of capture reagents, sequencing technologies and bioinformatics
will, however, most likely ultimately lead to exome and possibly
whole-genome sequencing as state-of-the art in molecular diag-
nostics of MODY.
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